专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2004108745A3 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES 审中-公开
标题翻译： 11-12双环红霉素衍生物
公开(公告)号：WO2004108745A3
公开(公告)日：2005-02-24
申请号：PCT/US2004013042
申请日：2004-04-28
申请人： ENANTA PHARM INC , LIU TONGZHU , PHAN LY TAM , OR YAT SUN , CHEN ZHIGANG , QIU YAO-LING
发明人： LIU TONGZHU , PHAN LY TAM , OR YAT SUN , CHEN ZHIGANG , QIU YAO-LING
IPC分类号： A61K31/70 , A61P31/04 , C07H17/00 , C07H17/08
CPC分类号： A61K31/70 , C07H17/00 , C07H17/08 , Y02P20/55
摘要： The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式（I）的化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。本发明还涉及包含前述化合物的药物组合物，用于向需要抗生素治疗的受试者施用。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

22. 发明申请

WO2004108745A2 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES 审中-公开
公开(公告)号：WO2004108745A2
公开(公告)日：2004-12-16
申请号：PCT/US2004/013042
申请日：2004-04-28
申请人： ENANTA PHARMACEUTICALS, INC. , LIU, Tongzhu , PHAN, Ly, Tam , OR, Yat, Sun , CHEN, Zhigang , QIU, Yao-Ling
发明人： LIU, Tongzhu , PHAN, Ly, Tam , OR, Yat, Sun , CHEN, Zhigang , QIU, Yao-Ling
IPC分类号： C07H17/00
CPC分类号： A61K31/70 , C07H17/00 , C07H17/08 , Y02P20/55
摘要： The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了具有抗菌性能的式（I）化合物或其药学上可接受的盐，酯或前药。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

23. 发明申请

WO2011031934A1 HEPATITIS C VIRUS INHIBITORS 审中-公开
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：WO2011031934A1
公开(公告)日：2011-03-17
申请号：PCT/US2010/048377
申请日：2010-09-10
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-ling , WANG, Ce , YING, Lu , PENG, Xiaowen , OR, Yat, Sun
发明人： QIU, Yao-ling , WANG, Ce , YING, Lu , PENG, Xiaowen , OR, Yat, Sun
IPC分类号： A01N43/36 , A61K31/40
CPC分类号： A61K31/40 , C07D207/28 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/08
摘要： The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上文所示的新的抗病毒化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物进行这种治疗的受试者中病毒（特别是HCV）感染的方法。

24. 发明申请

WO2010096462A1 LINKED DIIMIDAZOLE DERIVATIVES 审中-公开
标题翻译：连接的二咪唑衍生物
公开(公告)号：WO2010096462A1
公开(公告)日：2010-08-26
申请号：PCT/US2010/024447
申请日：2010-02-17
申请人： ENANTA PHARMACEUTICALS, INC , OR, Yat, Sun , PENG, Xiaowen , YING, Lu , CE, Wang , TANG, Datong , QIU, Yao-Ling
发明人： OR, Yat, Sun , PENG, Xiaowen , YING, Lu , CE, Wang , TANG, Datong , QIU, Yao-Ling
IPC分类号： A01N43/50 , A61K31/415
CPC分类号： C07D403/14 , A61K31/415 , A61K45/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K2300/00
摘要： The present invention discloses compounds of linked diimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA- containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的连接的二咪唑衍生物或其药学上可接受的盐，酯或前药的化合物。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

25. 发明申请

WO2006119417A1 PROCESSES FOR THE PREPARATION OF O-(6-PYRAZOL-1-YL-PYRIDIN-3-YLMETHYL)-HYDROXYLAMINE 审中-公开
标题翻译：制备O-（6-吡咯烷-1-基 - 吡啶-3-基甲基） - 羟基甲酰胺的方法
公开(公告)号：WO2006119417A1
公开(公告)日：2006-11-09
申请号：PCT/US2006/017131
申请日：2006-05-02
申请人： ENANTA PHARMACEUTICALS, INC. , WANG, Zhe , TANG, Datong , QIU, Yao-ling , KIM, Heejin , OR, Yat, Sun
发明人： WANG, Zhe , TANG, Datong , QIU, Yao-ling , KIM, Heejin , OR, Yat, Sun
IPC分类号： C07D401/04
CPC分类号： C07D401/04 , C07D401/14
摘要： The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-l-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 Al. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia).
摘要翻译：本发明一般涉及合成O-（6-吡唑-1-基 - 吡啶-3-基甲基） - 羟胺的新方法，其是合成桥联红霉素衍生物之一及其各自药学上的必需试剂 PCT申请WO 03/097659 A1中的可接受的盐。特别地，本发明涉及制备式（Ia）化合物的方法和中间体。

26. 发明申请

WO2006039263A2 NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES 审中-公开
标题翻译：新型双酚-9a-半胱氨酸衍生物
公开(公告)号：WO2006039263A2
公开(公告)日：2006-04-13
申请号：PCT/US2005/034578
申请日：2005-09-28
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , QIU, Yao-Ling , WANG, Guoqiang , NIU, Deqiang , PHAN, Ly, Tam
发明人： OR, Yat, Sun , QIU, Yao-Ling , WANG, Guoqiang , NIU, Deqiang , PHAN, Ly, Tam
IPC分类号： C07H17/08 , A61K31/7052
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) (II) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式I和II的化合物或其药学上可接受的盐，酯或前药：（I）（II）

27. 发明申请

WO2005070113A3 9N-SUBSTITUTED 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES 审中-公开
标题翻译： 9N取代的6-11双环红霉素衍生物
公开(公告)号：WO2005070113A3
公开(公告)日：2005-11-03
申请号：PCT/US2005000643
申请日：2005-01-07
申请人： ENANTA PHARM INC , QIU YAO-LING , NIU DEQIANG , WANG ZHE , PHAN LY TAM
发明人： QIU YAO-LING , NIU DEQIANG , WANG ZHE , PHAN LY TAM
IPC分类号： A01N43/04 , A61K31/70 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula (I), (II), (III), or (IV), or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: formulas (I), (II), (III), (IV), which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式（I），（II），（III）或（IV）的化合物或其外消旋物，对映异构体，区域异构体，盐，酯或前药：式），（IV），它们表现出抗菌性能。本发明还涉及包含前述化合物的药物组合物，用于向需要抗生素治疗的受试者施用。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

28. 发明申请

WO2012125900A1 2'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES 审中-公开
标题翻译： 2'-烯替代的核苷酸衍生物
公开(公告)号：WO2012125900A1
公开(公告)日：2012-09-20
申请号：PCT/US2012/029381
申请日：2012-03-16
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , MA, Jun , WANG, Guoqiang , KIM, In, Jong , LONG, Jiang , QIU, Yao-Ling
发明人： OR, Yat, Sun , MA, Jun , WANG, Guoqiang , KIM, In, Jong , LONG, Jiang , QIU, Yao-Ling
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： C07H19/06 , A61K31/7056 , A61K31/706 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/55 , A61K45/06 , A61K2300/00 , A61K31/426 , A61K31/13
摘要： The present invention relates to 2'-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside derivatives.
摘要翻译：本发明涉及通式（I）的2'-连烯取代的核苷衍生物：以及包含这些化合物的药物组合物以及治疗或预防HIV感染，HBV感染，HCV感染或异常细胞增殖的方法，包括给药所述化合物或组合物。此外，本发明包括制备这些化合物的方法，以及相关的β-D和β-L-核苷衍生物。

29. 发明申请

WO2011127350A1 HEPATITIS C VIRUS INHIBITORS 审中-公开
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：WO2011127350A1
公开(公告)日：2011-10-13
申请号：PCT/US2011/031690
申请日：2011-04-08
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , OR, Yat, Sun
发明人： QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , OR, Yat, Sun
IPC分类号： A01N43/50 , A01N43/52 , A61K31/415
CPC分类号： C07D498/18 , A61K31/4188 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/21 , A61K38/55 , A61K45/06 , C07D519/00 , C12N2770/24211 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

30. 发明申请

WO2011109037A1 COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION 审中-公开
标题翻译：作为HCV复制抑制剂的组合药物代谢
公开(公告)号：WO2011109037A1
公开(公告)日：2011-09-09
申请号：PCT/US2010/044591
申请日：2010-08-05
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , OWENS, Christopher, M. , BRASHER, Bradley, B. , QIU, Yao-Ling , JIANG, Lijuan
发明人： OR, Yat, Sun , OWENS, Christopher, M. , BRASHER, Bradley, B. , QIU, Yao-Ling , JIANG, Lijuan
IPC分类号： A01N43/00
CPC分类号： A61K31/13 , A61K31/4184 , A61K31/4196 , A61K31/437 , A61K38/13 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K38/212 , A61K45/06 , A61K2300/00
摘要： The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti- HCV activity.
摘要翻译：本发明涉及组合或串联用于治疗黄病毒性病毒感染的药物，例如丙型肝炎病毒（HCV），其中治疗包括施用有效抑制HCV功能的化合物 NS5A蛋白质和具有抗HCV活性的化合物或其组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式